This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Marcus R et al. (2005) CVP chemotherapy plus rituximab compared with CVP as first line treatment for advanced follicular lymphoma. Blood 105: 1417–1423
Forstpointner R et al. (2004) The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomised study of the German Low-Grade Lymphoma Study Group. Blood 104: 3064–3071
Hiddemann W et al. (2005) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) significantly improves the outcome of patients with advanced stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group (GLSG). Blood 106: 3725–3732
van Oers MH et al. (2006) Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomised phase 3 intergroup trial. Blood 108: 3295–3301
Acknowledgements
The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Ritchie, D. Is rituximab maintenance therapy useful following rituximab salvage in refractory or relapsed follicular lymphoma?. Nat Rev Clin Oncol 4, 402–403 (2007). https://doi.org/10.1038/ncponc0842
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncponc0842